ALZN: Alzamend Neuro, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 6.25
Enterprise Value ($M) 2.15
Book Value ($M) 3.75
Book Value / Share 0.69
Price / Book 1.66
NCAV ($M) 3.51
NCAV / Share 0.65
Price / NCAV 1.78

Profitability (mra)
Return on Invested Capital (ROIC) -1.56
Return on Assets (ROA) -5.95
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 3.80
Current Ratio 3.80

Balance Sheet (mrq) ($M)
Current Assets 4.77
Assets 5.01
Liabilities 1.25
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -9.94
Net Income -9.95

Cash Flow Statement (mra) ($M)
Cash From Operations -8.27
Cash from Investing -0.15
Cash from Financing 3.65

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-02 13D/A Ault Milton C Iii 40.30 62.95

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-12-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q
2024-09-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q
2024-07-30 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended April 30, 2024 ¨ TRANSITION REPORT PURSUANT TO SECTION
2024-03-25 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-14 25,958 67,843 38.26
2025-01-13 21,514 66,131 32.53
2025-01-10 35,326 133,462 26.47

(click for more detail)

Similar Companies
ALGS – Aligos Therapeutics, Inc. ALTS – JanOne Inc.
ALVR – AlloVir, Inc. ANEB – Anebulo Pharmaceuticals, Inc.
ANIX – Anixa Biosciences, Inc.


Financial data and stock pages provided by
Fintel.io